UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Helpful or harmful? The therapeutic potential of medications with varying degrees of abuse liability in the treatment of substance use disorders
Both ketamine and psychedelics may be useful in alcohol, cocaine & opioid use disorders.
Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States
These findings add to a growing consensus amongst experts that the current drug policy is not scientifically coherent.
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Relative to baseline, reductions in depressive symptoms were observed at 2 and 4 weeks.
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world
Here, we sought to develop a new scale to measure connectedness as a construct with these multiple domains.
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
We conclude that expectation underlies at least some of the anecdotal benefits attributed to microdosing with psilocybin mushrooms.
Biden administration plans for legal psychedelic therapies within two years
President Joe Biden’s administration “anticipates” that regulators will approve MDMA and psilocybin within the next two years for for PTSD and depression, respectively.
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
This paper provides a critical review of several possible mechanisms at different levels of analysis underlying the effects and therapeutic potential of psychedelics.
Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience
In this mixed methods online suWe aimed to develop an understanding of frequently used psych
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial
At-home KAT response and remission rates indicated rapid and significant antidepressant and anxiolytic effects.
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey
Here, we report results from an online survey conducted between August 2020 and July 2021 in a population of 250 chronic pain sufferers.
Psychedelics, mystical experience, and therapeutic efficacy: A systematic review
In this review, 12 studies of psychedelic therapy utilizing psilocybin, ayahuasca, or ketamine were analyzed for association between mystical experience and symptom reduction.
From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary development of the Relaxed Beliefs Questionnaire (REB-Q).
We report the first empirical evidence that the relaxation and revision of negative self-belief confidence mediates positive psychological outcomes.
Psychedelics in the treatment of unipolar and bipolar depression
This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression.
Decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees
Results suggest rapid and persisting (up to 1 week) anxiolytic effects in individuals with sub-clinical anxiety symptoms